This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jan;9(2):153-5.

doi: 10.4161/cbt.9.2.10760. Epub 2010 Jan 26.

Targeting plasma membrane GRP78 for cancer growth inhibition

Steve Schwarze¹, Vivek M Rangnekar

Affiliations

PMID: 20026905
DOI: 10.4161/cbt.9.2.10760

Comment

Targeting plasma membrane GRP78 for cancer growth inhibition

Steve Schwarze et al. Cancer Biol Ther. 2010 Jan.

. 2010 Jan;9(2):153-5.

doi: 10.4161/cbt.9.2.10760. Epub 2010 Jan 26.

Authors

Steve Schwarze¹, Vivek M Rangnekar

Affiliation

¹ Department of Biochemistry and Molecular Biology, University of Kentucky, Lexington, KY, USA.

PMID: 20026905
DOI: 10.4161/cbt.9.2.10760

No abstract available

PubMed Disclaimer

Comment on

Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells.
Misra UK, Pizzo SV. Misra UK, et al. Cancer Biol Ther. 2010 Jan;9(2):142-52. doi: 10.4161/cbt.9.2.10422. Epub 2010 Jan 26. Cancer Biol Ther. 2010. PMID: 20368692

Similar articles

Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells.
Misra UK, Pizzo SV. Misra UK, et al. Cancer Biol Ther. 2010 Jan;9(2):142-52. doi: 10.4161/cbt.9.2.10422. Epub 2010 Jan 26. Cancer Biol Ther. 2010. PMID: 20368692
New solid tumor targets for therapeutic monoclonal antibodies.
Papkoff J. Papkoff J. Expert Opin Ther Targets. 2007 May;11(5):585-8. doi: 10.1517/14728222.11.5.585. Expert Opin Ther Targets. 2007. PMID: 17465718
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.
Xu L, Chen S, Bergan RC. Xu L, et al. Oncogene. 2006 May 18;25(21):2987-98. doi: 10.1038/sj.onc.1209337. Oncogene. 2006. PMID: 16407830
Novel therapeutic approaches to advanced prostate cancer.
Armstrong AJ, Carducci MA. Armstrong AJ, et al. Clin Adv Hematol Oncol. 2005 Apr;3(4):271-82. Clin Adv Hematol Oncol. 2005. PMID: 16167000 Review.
Update on HER-kinase-directed therapy in prostate cancer.
Gross ME, Jo S, Agus DB. Gross ME, et al. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.

See all similar articles

Cited by

Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.
Zheng Y, Wang N, Wang S, Pan B, Yang B, Zhang J, Wang X, Wang Z. Zheng Y, et al. Clin Transl Med. 2023 Feb;13(2):e1119. doi: 10.1002/ctm2.1119. Clin Transl Med. 2023. PMID: 36808887 Free PMC article. No abstract available.
The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases.
Eggleton P, De Alba J, Weinreich M, Calias P, Foulkes R, Corrigall VM. Eggleton P, et al. J Cell Mol Med. 2023 Feb;27(3):322-339. doi: 10.1111/jcmm.17669. Epub 2023 Jan 18. J Cell Mol Med. 2023. PMID: 36651415 Free PMC article. Review.
Targeting protein quality control pathways in breast cancer.
Sannino S, Brodsky JL. Sannino S, et al. BMC Biol. 2017 Nov 16;15(1):109. doi: 10.1186/s12915-017-0449-4. BMC Biol. 2017. PMID: 29145850 Free PMC article. Review.
Targeting the unfolded protein response in cancer.
Ojha R, Amaravadi RK. Ojha R, et al. Pharmacol Res. 2017 Jun;120:258-266. doi: 10.1016/j.phrs.2017.04.003. Epub 2017 Apr 8. Pharmacol Res. 2017. PMID: 28396092 Free PMC article. Review.
Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.
Han KS, Li N, Raven PA, Fazli L, Frees S, Ettinger S, Park KC, Hong SJ, Gleave ME, So AI. Han KS, et al. Oncotarget. 2015 Oct 27;6(33):34818-30. doi: 10.18632/oncotarget.5397. Oncotarget. 2015. PMID: 26472187 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Taylor & Francis
Other Literature Sources
- The Lens - Patent Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

-